Advertisement

Histone deacetylases in kidney development: implications for disease and therapy.

06:24 EDT 20th June 2013 | BioPortfolio

Summary of "Histone deacetylases in kidney development: implications for disease and therapy."

Histone deacetylases (HDACs) are an evolutionarily conserved group of enzymes that regulate a broad range of biological processes through removal of acetyl groups from histones as well as non-histone proteins. Recent studies using a variety of pharmacological inhibitors and genetic models of HDACs have revealed a central role of HDACs in control of kidney development. These findings provide new insights into the epigenetic mechanisms underlying congenital anomalies of the kidney and urinary tract (CAKUT) and implicate the potential of HDACs as therapeutic targets in kidney diseases, such as cystic kidney diseases and renal cell cancers. Determining the specific functions of individual HDAC members would be an important task of future research.

Affiliation

Department of Pediatrics, Section of Pediatric Nephrology, Tulane University Health Sciences Center, 1430 Tulane Avenue, SL-37, New Orleans, LA, 70112, USA.

Journal Details

This article was published in the following journal.

Name: Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Pages:

Links

Medical and Biotech [MESH] Definitions

Histone Deacetylases

Deacetylases that remove N-acetyl groups from amino side chains of the amino acids of HISTONES. The enzyme family can be divided into at least three structurally-defined subclasses. Class I and class II deacetylases utilize a zinc-dependent mechanism. The sirtuin histone deacetylases belong to class III and are NAD-dependent enzymes.

Group Iii Histone Deacetylases

A subclass of histone deacetylases that are NAD-dependent. Several members of the SIRTUINS family are included in this subclass.

Histone Deacetylase Inhibitors

Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains.

Disease Management

A broad approach to appropriate coordination of the entire disease treatment process that often involves shifting away from more expensive inpatient and acute care to areas such as preventive medicine, patient counseling and education, and outpatient care. This concept includes implications of appropriate versus inappropriate therapy on the overall cost and clinical outcome of a particular disease. (From Hosp Pharm 1995 Jul;30(7):596)

Proto-oncogene Proteins C-bcl-6

A DNA-binding protein that represses GENETIC TRANSCRIPTION of target genes by recruiting HISTONE DEACETYLASES. Aberrant Blc-6 expression is associated with certain types of human B-CELL LYMPHOMA.

PubMed Articles [ 30703 Associated PubMed Articles listed on BioPortfolio]

Histone deacetylases and their functions in plants.

Histone deacetylases (HDACs) mediate histone deacetylation and act in concert with histone acetyltransferases to regulate dynamic and reversible histone acetylation which modifies chromatin structure...

Histone deacetylase: A potential therapeutic target for fibrotic disorders.

Histone deacetylases (HDACs) are enzymes that balance the acetylation activities of histone acetyltransferases (HATs) on chromatin remodeling and play essential roles in regulating gene transcription....

NMR profiling of histone deacetylase and acetyl-transferase activities in real time.

Histone deacetylases (HDACs) and Histone acetyl-transferases (HATs) are universal regulators of eukaryotic transcriptional activity and emerging therapeutic targets for human diseases. Here we describ...

HDAC2 is required for chromatin condensation and subsequent enucleation of cultured mouse fetal erythroblasts.

Background. Mammalian erythroid cells undergo chromatin condensation and enucleation in their final stages of differentiation. We previously reported that Rac GTPases and their downstream target mDia2...

Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy.

Histone deacetylases (HDACs) influence many cellular processes, including the modulation of signal transducer and activator of transcription activity (STAT) in response to interferon (IFN). To identif...

Clinical Trials [ 4905 Associated Clinical Trials listed on BioPortfolio]

A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors

Chemotherapy resistance, either innate or acquired requires for its development, expression changes on a large number of genes therefore, it has been hypothesized that epigenetic-mediated...

Uric Acid and Long-term Outcomes in Chronic Kidney Disease

Patients in the earlier stages of Chronic kidney disease (CKD) are at risk both for the development of end-stage renal disease (ESRD) (define by the requirement for dialysis or kidney tran...

Polycystic Kidney Disease Data Repository

Autosomal dominant polycystic kidney disease (PKD) is the most common inherited kidney disease, affecting more than 400,000 people in the U.S. and 5 million people worldwide. PKD is the 4t...

Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)

The investigators would like to study the role of phosphorus metabolism in the development of certain hormonal problems in people with chronic kidney disease. More specifically, the goals...

Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria

Patients with chronic kidney disease and albuminuria are at increased risk of developing cardiovascular disease which is often associated with hypertension, left ventricular hypertrophy, e...

Search BioPortfolio: